Ignyta

Ignyta Inc is the American company applying methods of precision medicine and molecular diagnostics to treatment of rare forms of cancer diseases and developing antineoplastic medicines. The company is based in San Diego (the USA, California).

2017: Acquisition by Roche company

As it became known at the end of December, 2017, the Swiss pharmaceutical company Roche buys the American company Ignyta Inc specializing in identification and treatment of patients with the cancer diseases bearing specific rare mutations — the corresponding agreement of the company was reached on December 22.

Transaction amount will be $1.7 billion – thus, the Roche company will pay $27 for each stock Ignyta that is 75% more than their cost at the time of closing of biddings on December 21 at the NASDAQ exchange. The transaction is already approved by Boards of Directors of both companies and, as expected, will be closed in the first half of 2018.^[1]

Thanks to this acquisition of Roche expects to expand the portfolio of onkopreparat. In particular, the company is interested in the medicine entrectinib developed by Ignyta for treatment of non-small cell cancer of lung which already passes clinical trials. The linear molecule Ignyta entrectinib is inhibitor of a CNS active tyrosinekinase and is developed for tumors which contain merges of oncogenes of ROS1 or NTRK.^[2]

Notes